loss heterozygos fluoresc situ hybrid fish studi shown delet 19q highli preval oligodendroglioma howev tumor comprehens screen alter chromosom dosag studi us arrai-base compar genom hybrid cgha map bac dna screen alter oligodendroglioma grade grade iii grade mix oligoastrocytoma grade grade grade most frequent aberr loss case 19q case combin loss 1p/19q case addit delet 10q 11p 13q observ case respect loss whole chromosom case respect gain 10p 11q case respect gain whole chromosom patient minim alter region detect cgha involv chromosom band 1p36.32 4q33 5p15 8q24 11p15 19q13.3 univari analysi case suggest combin delet 19q associ better surviv 0.03 addit gain oligodendroglioma strongli associ poor outcom 0.002 associ poor diseas outcom alter low preval pure oligodendroglioma includ loss 12q gain 10q summari oligodendroglioma cgha abl detect novel small alter chromosom dosag previous detect method addit find support hypothes oligodendroglioma classifi sever group cgha analysi specif alter genet dosag biolog clinic signific
allel loss chromosom arm 19q associ favor respons chemotherapi good prognosi anaplast oligodendroglioma patient molecular mechan respons relationship yet unknown dna repair enzym -methylguanin dna methyltransferas mgmt caus resist dna-alkyl drug commonli us treatment anaplast oligodendroglioma malign glioma report analysi oligodendrogli tumor mgmt promot methyl well mrna protein express us sequenc sodium bisulfit-modifi dna determin methyl statu cpg site mgmt promot tumor detect mgmt promot hypermethyl defin methyl sequenc cpg site real-time revers transcript-pcr show reduc mgmt mrna level rel non-neoplast brain tissu major tumor hypermethyl similarli immunohistochem analysi show small fraction mgmt posit tumor cell mgmt promot hypermethyl significantli frequent percentag methyl cpg site investig mgmt promot fragment significantli higher tumor loss heterozygos chromosom arm 19q compar tumor allel loss chromosom arm taken togeth data suggest mgmt hypermethyl low absent express frequent oligodendrogli tumor like contribut chemosensit tumor
epigenet silenc -methylguanin-dna methyltransferas mgmt promot methyl confer cancer cell increas sensit alkyl chemotherapeut agent higher suscept tp53 transit mutat aim studi assess correl promot methyl mgmt gene tp53 mutat clinic characterist malign astrocytoma analyz mgmt promot methyl tp53 mutat malign astrocytoma anaplast astrocytoma glioblastoma multiform treat prospect 4-amino-2-methyl-5-pyrimidinyl methyl-3-2 2-chloroethyl -3-nitrosourea interferon-beta radiat therapi evalu clinic us mgmt promot methyl found newli diagnos malign astrocytoma clear trend exist mgmt methyl transit mutat tp53 0.0596 patient mgmt-methyl tumor displai greater chanc respond adjuv therapi compar mgmt-unmethyl tumor 0.0393 tp53 mutat significantli associ clinic respons 0.1310 neither mgmt methyl nor tp53 mutat signific effect prognosi whole popul presenc mgmt methyl emerg signific predictor longer surviv exclus analyz patient glioblastoma multiform find highlight import mgmt methyl specif predict factor respons nitrosourea chemotherapi
malign glioma compris major primari human brain tumor 800 case report year usa prognosi remain dismal despit numer attempt improv convent therapeut modal much effort devot explor altern form treatment immunotherapi identif potenti target structur highli overexpress brain tumor crucial prerequisit activ immun defens malign glioma cell screen express databas gene highli express glioblastoma multiform gbm identifi pit-oct-unc pou cooper transcript factor sox11 known crucial involv brain develop analysi express pattern sox11 differ normal adult fetal tissu multipl tissu dot blot highli sensit quantit pcr assai confirm select overexpress sox11 fetal brain tissu examin tissu specimen obtain malign glioma normal brain quantit real-time pcr q-rt-pcr reveal upregul sox11 almost tumor sampl 15/16 compar pool normal brain seventi-five percent tumor sampl 12/16 show 600-fold overexpress conclud downregul sox11 adult brain express reactiv tumorigenesi sox11 repres promis novel molecular target adjuv therapi malign glioma
gene express profil tissu-specif reflect germ-line-driven express pattern across tissu type previous us target pharmacolog approach identifi germ-line polymorph singl gene thiopurin methyltransferas associ risk irradi- chemotherapi-induc secondari brain tumor children acut lymphoblast leukemia identifi addit candid genet risk factor ident treat patient compar gene express profil diagnost blast develop irradi-associ brain tumor profil weight rank regress us identifi probe set associ time-depend develop brain tumor k-mean cluster identifi group differ significantli cumul incid brain tumor 0.012 permut analysi us estim probabl 0.18 obtain cluster chanc linear discrimin analysi time-independ categor outcom us identifi probe set express differenti group patient permut analys 000 us estim probabl select probe set chanc 0.055 five probe set common time-independ time-depend method distinguish gene involv neural growth fgfr1 nuclear traffick hnrpl kpnb1 data suggest gene express profil access tissu identifi target involv therapi-relat malign unrel tissu
viru jcv viru bkv simian viru sv40 associ human brain tumor polyomavirus shown induc brain tumor experiment infect anim sever studi found polyomaviru genom sequenc human brain tumor tissu us polymeras chain reaction pcr other inconsist previou find due part small sampl size differ underli patient popul laboratori techniqu qualiti control measur assess role polyomavirus human brain tumor address inconsist previou report investig preval viral sequenc seri 225 brain tumor tissu specimen independ laboratori pcr follow southern hybrid perform nation institut neurolog disord stroke nind real-time quantit pcr perform same tissu john hopkin univers jhu tumor amplifi dna test polyomaviru sequenc posit neg control tissu includ specimen mask amplifi dna detect 225/225 100 tumor nind contain polyomaviru sequenc jcv-posit bkv-posit sv40-posit jhu laboratori amplifi dna 165/225 tumor tumor test posit sv40 tumor test posit both laboratori result mask qualiti control tissu concord laboratori nucleotid sequenc jcv bkv sv40 rare present larg seri adult pediatr brain tumor
express coxsacki adenoviru receptor car downregul malign glioma cell line bare detect high-grade primari astrocytoma glioblastoma multiform determin effect forc car express invas growth human glioma cell line u87-mg doe express car retrovir mediat express full-length car u87-mg cell affect monolay growth vitro reduc glioma cell invas 3-dimension spheroid model furthermor xenograft experi intracerebr implant glioma cell express full-length car result tumor significantli reduc volum compar tumor gener control vector-transduc u87-mg cell contrast u87-mg cell express transmembran car delet entir cytoplasm domain except first intracellular juxtamembran cystein amino acid rate invas tumor growth similar control cell differ behavior form car due improp cell surfac local cytoplasm delet car determin compar immunostain unpermeabil cell equival adenovir transduct cell similar extent fraction lipid-rich domain taken togeth result suggest decreas loss car express malign glioma confer select advantag growth invas tumor
imag plai fundament role manag children brain tumour seri techniqu commonli group under head function imag promis give inform properti biolog characterist tissu therebi ad structur inform avail current imag epsrc fund workshop bring togeth clinician children's cancer studi group scientif expert field identifi clinic problem childhood brain tumour address function imag develop clinic test bed appli evalu develop technolog present discuss session workshop summaris review current 'state art' rapidli develop area provid kei output workshop agreement seri hypothes test carefulli design clinic studi
object exogen applic t11ts/slfa3 glioma model shown regress tumor load through immunopotenti mechanist modul interact immunolog synaps format result effect glioma regress search delin immunotherapeut efficaci t11ts method purif t11ts/slfa3 sheep erythrocyt glycoprotein character sd-page analysi glycoprotein stain modulatori effect t11ts applic glioma anim studi cd2 mhc class express peripher lymphocyt pmn macrophag intracrani microglia flowcytometr analysi final apoptot kill brain cell studi through annevin-v express measur fragment cytoplasm dna elisa result compar healthi normal counter-part cd2 receptor downregul enu treatment lymphocyt pmn upregul three consecut dose t11ts splenic antigen present macrophag intracrani mocroglia shown cd2 mhc class modul simultan differ subtyp receptor studi reveal signific boost immun compet cell most effect second dose t11ts wherea third dose regulatori effect sharp increas apoptosi brain cell found phosphatidylserin extern presenc fragment dna cytoplasm applic t11ts consecut dose result immun potenti conclus receptor studi reveal modul cd2 mhc class two import constitu immunolog synaps successfulli help form tcr-p-mhc complex provid requir co-stimul activ potenti immun effector machineri direct abrog glioma apoptosi signifi t11ts immunotherapeut probe
purpos estrogen receptor beta erbeta second identifi receptor mediat effect estrogen target tissu role erbeta cancer pathobiolog larg unknown becaus specif antibodi avail recent initi studi shown erbeta express declin breast ovarian prostat colon carcinoma tamoxifen synthet anti-estrogen compound mix agonist/antagonist estrogen receptor alpha eralpha pure antagonist erbeta moder benefici effect human astrocyt neoplasm howev most publish studi agre glial tumor express eralpha purpos studi explor express erbeta astrocyt neoplasm method erbeta express monitor immunohistochem case astrocytoma grade grade i-iv adjac non-neoplast brain tissu result moder strong nuclear immunoposit obtain non-neoplast astrocyt low-grade astrocytoma wherea major high-grade tumor immunoneg displai weak immunoreact progress declin erbeta express parallel increas tumor grade conclus much erbeta possibl express astrocyt decreas express plai import role astrocyt tumor initi potenti respons glial neoplasm tamoxifen
purpos review role amifostin wr-2721 amelior radiat-induc central nervou system cn toxic materi method literatur review present preliminari anim experi design test efficaci both intrathec subcutan applic amifostin result despit inabl cross blood-brain barrier amifostin appear promis becaus protect blood vessel radiat-induc damag vascular damag on most import compon develop cn toxic radiotherapi furthermor increas permeabl blood-brain barrier fraction radiotherapi allow penetr amifostin three anim studi system administr found posit result brain irradi differ fraction schedul total dose amifostin dose on studi amifostin given radiotherapi show protect suggest time drug applic crucial data suggest intrathec system administr protect spinal cord well experi spinal cord irradi system administr effect intrathec regard cn protect optimum dose amifostin yet determin conclus sever independ experi provid preliminari evid modul radiat respons cn vivo system administr amifostin possibl feasibl addit studi warrant investig protect effect differ regimen administr clinic relev fraction regimen longer follow-up
background recent demonstr high select long retent p-[123i]iodo-l-phenylalanin ipa-123 diagnost purpos glioma here describ potenc iodin-131-label analogu p-[131i]iodo-l-phenylalanin ipa-131 experiment treatment glioma materi method two human glioma cell cultur 15/20 rat c6-glioma expos ipa-131 result 24-h-exposur cell number glioma cell cultur reduc respect four five untreat rat di 8-24 dai implant verifi tumour seven anim di despit therapi soon healthier gain bodi weight sacrif dai implant time surviv treat anim significantli prolong &lt 0.05 autopsi instead tumour substanc defect surround pre-exist parenchyma infiltr probabl tumour cell discern reactiv astrocyt lymphocyt monocyt multinuclear giant cell conclus ipa-131 promis activ human glioma cell vitro experiment glioma vivo
background multifoc tumor recurr glioblastoma patient describ case two recent studi treat newli diagnos glioblastoma patient continu high-dose tamoxifen tam report increas incid multifoc tumor recurr 45.5 studi patient patient method fifti newli diagnos patient glioblastoma treat cycl carboplatin continu high-dose tam radiotherapi tumor progress determin follow-up mri studi 3-month interv categor local multifoc result multifoc tumor recurr found studi patient compar tumor remain local multifoc tumor recurr character significantli longer median time tumor progress week breslow test 0.0123 multifoc tumor recurr mainli observ initi respons studi treatment wherea local regrowth associ initi treatment failur i.e progress diseas conclus associ pattern tumor recurr type respons tam treatment suggest acquir resist tam import contribut mechan develop multifoc glioblastoma diseas
